Catalent goes public in a successful IPO
Blackstone Group-owned CDMO nets over $800 million
Catalent Inc. (Somerset, NJ), spun out of Cardinal Health back in 2007, has now taken the “next step in our growth journey” by going public, at CTLT on the New York Stock Exchange. Blackstone Group, the private investment firm which acquired most of the business, will retain majority ownership. The money raised will be used primarily to retire debt the company has undertaken in the past few years.
Catalent’s financial filings indicate the company grossed about $1.8 billion in 2013, in three business segments: Oral Technologies (about 66% of revenue). Medication Delivery Solutions (about 12%) and Development and Clinical Services (about 22%). That makes it a leader in clinical development and manufacturing organizations (CDMOs) globally. The oral technologies group has 14 manufacturing and development plants, located globally. Recent investments include expansions in its Softgel and clinical supply business in China and Brazil, a new Biologics Center of Excellence in Madison, WI and an expansion of its oral technologies manufacturing site in Winchester, KY.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
